Section ofEndocrinology 909 rate of 50 pg/h over a period of eight hours, and plasma 11-OHCS levels were estimated twohourly. The second day, metyrapone ditartrate was infused in addition to Synacthen from the third to the eighth hour. Three rates of infusion of metyrapone ditartrate were used: 200 mg during the third and fourth hours, 600 mg. during the fifth and sixth, and 1 2 g during the seventh and eighth. Plasma metyrapone and 1 1-OHCS levels were measured at the end of each two-hour period. It was found that a plasma metyrapone level of 15 jig/100 ml suppressed plasma 1 1-OHCS 25%, 46 ,ug/100 ml suppressed them 72%, and 245 pg/100 ml suppressed them 85 %.
rate of 50 pg/h over a period of eight hours, and plasma 11-OHCS levels were estimated twohourly. The second day, metyrapone ditartrate was infused in addition to Synacthen from the third to the eighth hour. Three rates of infusion of metyrapone ditartrate were used: 200 mg during the third and fourth hours, 600 mg. during the fifth and sixth, and 1 2 g during the seventh and eighth. Plasma metyrapone and 1 1-OHCS levels were measured at the end of each two-hour period. It was found that a plasma metyrapone level of 15 jig/100 ml suppressed plasma 1 1-OHCS 25%, 46 ,ug/100 ml suppressed them 72%, and 245 pg/100 ml suppressed them 85 %.
Metyrapone and its metabolites have been extracted from plasma and urine. The predominant metabolite is probably reduced metyrapone, but there are more polar metabolites.
The metyrapone test and the insulin hypoglycwemia test were carried out in 8 patients, 6 of whom had had ablation of the pituitary with yttrium-90 and two of whom had Sheehan's syndrome. It was found that when pituitary destruction was either total or very incomplete the two tests gave comparable results, but that in intermediate cases the metyrapone test appeared to be more sensitive in detecting residual secretion of corticotrophin. The administration of a pyrogen to 40 subjects without endocrine disease resulted in a mean increase in plasma cortisol of 22-1 ,ug/100 ml. Twenty-nine patients with lesions of the pituitary or hypothalamus were studied, and 15 showed a normal response, but in these patients other tests of pituitary-adrenal function, metyrapone and vasopressin, gave a higher proportion of abnormal results. An attempt was made to determine the site of action of pyrogen. The suppression of fever by an antipyretic demonstrated that the febrile and steroid responses were dissociated. Extensive use of a wide variety of drugs known to affect the central nervous system failed to demonstrate any significant depression of the pyrogen response. In particular,morphine failed to affect the pyrogen response whereas it completely suppressed the reaction to vasopressin. These findings, together with other evidence, support the view that pyrogen acts mainly at the level of the pituitary, rather than through the medium of the central nervous system. The assessment of adrenocorticotrophic hormone (ACTH) secretion in man is difficult by direct assay. Indirect methods are therefore used, such as the administration of ACTH and metyrapone, the study of diurnal plasma cortisol values, the response to insulin-induced hypoglycaemia and to lysine-8-vasopressin administration, and the response to the intravenous administration of pyrogen. Each of these methods tests the hypothalamic-pituitary-adrenocortical axis in a different way but it needs to be stressed that, with the exception of ACTH administration, in none of the tests is the precise mechanism of the mode of action generally agreed. It is necessary to understand the limitations of each test, otherwise a fault in diagnosis may be made.
ACTH tests usually use a physiological excess and are carried out to show that the adrenal gland responds normally to its trophic hormone. Our previous work has shown that the synthetic tetracosapeptide Synacthen mimics closely the natural hormone. We have used it widely and found it best to test the sensitivity of the adrenal cortex to the infusion of physiological amounts-of tetracosactide. The intravenous administration of 1 -25 pg for one hour into normal subjects produces a plasma 1 1-hydroxycorticosteroid (11-OHCS) increment of about 13 ,g/100 ml (range 7-2-24-4 pg/100 ml). This is about the same increment of ll-OHCS which is produced by insulin hypoglycemia or by lysine-8-vasopressin administration. It is about two-thirds the increment produced by maximal stimulation by ACTH administered for one hour. When patients with suspected pituitary insufficiency are tested, adrenal insufficiency may be demonstrated by the infusion of submaximal amounts of ACTH whereas the administration of supramaximal amounts may give normal results.
There is in most normal subjects a well-defined diurnal plasma cortisol pattern, the peak levels being found in the morning from about 6 a.m. to 10 a.m., and the lowest levels being found from about midnight to 4 a.m. The diurnal changes in cortisol secretion, however, may vary by some hours from patient to patient so that frequent samples must be taken, which is a practical and helpful procedure with indwelling plastic catheters.
Metyrapone administration as a test of hypopituitarism suffers from a number of disadvantages, mainly because it is difficult to interpret the results when the initial urinary steroid excretion (17-KGS, 17-OHCS) is low. The response may be negative in patients with myxoedema, liver disease or pregnancy or when certain drugs are given such as cestrogens, anabolic steroids or chlorpromazine. Further, because of the marked diurnal sensitivity to metyrapone administration it is most important that a suitable dose be given at midnight and at 4 a.m. or a false negative result may be obtained.
Insulin hypoglycwemia is of great value in testing the hypothalamic-pituitary-adrenal axis but it must be carried out with due attention to its limitations. It is important that the fasting plasma glucose is reduced to at least 40% of its initial value within twenty to thirty minutes of the administration of the insulin. Hypoglycaemia of less intensity may fail to elicit a response. Patients with obesity and Cushing's disease may be unresponsive as are patients who have previously received glucocorticoids. The test must be carried out under skilled medical supervision and otherwise is unsuitable as a screening procedure.
Lysine-8-vasopressin administration is a useful test of pituitary function and is best carried out by intramuscular administration of 10 units of the synthetic peptide. The test should be performed in the afternoon rather than in the morning because of the greater sensitivity at this time. False negative responses are found sometimes without apparent explanation but often when patients have been given glucocorticoids before. The test is not without risk and should not be carried out on patients suspected of coronary insufficiency. The response of the 'normal' child to adrenocorticotrophic hormone and the measurement of his cortisol production rate have been reasonably well standardized. These tests can be used to investigate pathological conditions. The use of the metyrapone test in children has been evaluated, and it has been concluded that it is unsatisfactory. The use of pyrogen and lysine vasopressin to stimulate the pituitary-adrenal axis will be discussed. The results of a study comparing the effects of long-term corticosteroids, a combination of corticosteroids and ACTH, and ACTH alone on the growth velocity of children is described. Growth velocity is decreased by corticosteroids leading to stunting of growth whereas ACTH, in sufficient doses to control the signs and symptoms of the disease being treated, increases the growth velocity.
The plasma cortisol response to insulininduced hypoglycLemia has been investigated in a group of normal adults, patients on long-term steroids and children on long-term ACTH: (a) Only 3 of 24 patients on long-term corticosteroids had a normal plasma cortisol response to intravenous insulin; the response obtained is dose dependent. (b) Twelve of 13 children on longterm ACTH gave a normal response in plasma cortisol following intravenous insulin; previous steroid therapy affected the maximum level of plasma cortisol attained after insulin. From this study we conclude that ACTH does not suppress the pituitary-adrenal axis to the same extent as long-term corticosteroids. Anabolic adrenal steroids which are suppressed on corticosteroid therapy may be secreted on ACTH therapy.
The plasma growth hormone response to insulin-induced hypoglycemia has been studied in a group of normal adults, patients on long-term corticosteroids and patients on ACTH. (a) Corticosteroids inhibit the plasma growth hormone response and the effect is partly dose dependent. (b) Children on long-term ACTH have a plasma growth hormone response which falls within the normal adult range. (c) The growth hormone response is independent of the cortisol response to insulin induced hypoglycemia. (d) ACTH per se does not stimulate growth hormone secretion. The difference in growth hormone response to insulin-induced hypoglycemia may be a factor in accounting for the difference in growth velocity observed between the groups treated with ACTH and with corticosteroids. A radioimmunological method was used to detect antibodies to porcine ACTH in children on long-term therapy with porcine ACTH. Thirteen of 19 children had detectable antibodies to porcine
